Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.

See What's Going on With the Solar Industry

Ahmed Hamdy Biography and Net Worth

CEO of Vincerx Pharma

Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from February 2013 to February 2016. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Dr Hamdy has served as a clinical advisor and member of the board of directors of Andes Biotechnologies, a nucleic acid-based drug discovery and development company, since September 2016, as a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz, since April 2019, and as a member of the Palo Alto Medical Foundation President’s Council since March 2016.

Dr. Hamdy received a MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt.

What is Ahmed Hamdy's net worth?: The estimated net worth of Ahmed Hamdy is at least $96,625.60 as of December 14th, 2022. Dr. Hamdy owns 73,760 shares of Vincerx Pharma stock worth more than $96,626 as of February 6th. This net worth estimate does not reflect any other assets that Dr. Hamdy may own. Additionally, Dr. Hamdy receives an annual salary of $614,910.00 as CEO at Vincerx Pharma. Learn More about Ahmed Hamdy's net worth.
How old is Ahmed Hamdy?: Dr. Hamdy is currently 57 years old. There are 3 older executives and no younger executives at Vincerx Pharma. Learn More on Ahmed Hamdy's age.
What is Ahmed Hamdy's salary?: As the CEO of Vincerx Pharma, Inc., Dr. Hamdy earned a total compensation package of $614,910.00 in 2021. Dr. Hamdy earned a salary of $460,000.00, a bonus of $148,925.00, and other compensation of $5,985.00. Learn More on Ahmed Hamdy's salary.
How do I contact Ahmed Hamdy?: The corporate mailing address for Dr. Hamdy and other Vincerx Pharma executives is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. Vincerx Pharma can also be reached via phone at 650-800-6676. Learn More on Ahmed Hamdy's contact information.
Has Ahmed Hamdy been buying or selling shares of Vincerx Pharma?: Ahmed Hamdy has not been actively trading shares of Vincerx Pharma in the last ninety days. Most recently, on Wednesday, December 14th, Ahmed Md Hamdy bought 35,280 shares of Vincerx Pharma stock. The stock was acquired at an average cost of $0.87 per share, with a total value of $30,693.60. Following the completion of the transaction, the chief executive officer now directly owns 73,760 shares of the company's stock, valued at $64,171.20. Learn More on Ahmed Hamdy's trading history.
Who are Vincerx Pharma's active insiders?: Vincerx Pharma's insider roster includes Laura Bushnell (Director), Ahmed Hamdy (CEO), Raquel Izumi (Insider), Andrew McDonald (Director), Alexander Seelenberger (CFO), and Tom Thomas (Insider). Learn More on Vincerx Pharma's active insiders.
Are insiders buying or selling shares of Vincerx Pharma?: During the last year, Vincerx Pharma insiders bought shares 6 times. They purchased a total of 161,618 shares worth more than $205,515.04. The most recent insider tranaction occured on December, 14th when insider Raquel E Izumi bought 28,738 shares worth more than $25,289.44. Insiders at Vincerx Pharma own 23.6% of the company. Learn More about insider trades at Vincerx Pharma.
Information on this page was last updated on 12/14/2022.

Ahmed Hamdy Insider Trading History at Vincerx Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/14/2022	Buy	35,280	$0.87	$30,693.60	73,760
6/23/2022	Buy	24,200	$1.41	$34,122.00	38,480
12/22/2021	Buy	6,450	$10.02	$64,629.00

Ahmed Hamdy Buying and Selling Activity at Vincerx Pharma

Vincerx Pharma Company Overview

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Today's Range

Now: $1.31

$1.31

$1.40

50 Day Range

MA: $0.99

$0.64

$1.51

2 Week Range

Now: $1.31

$0.63

$7.14

Volume

26,202 shs

Average Volume

100,213 shs

Market Capitalization

$27.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

The Safest Option in Trades!

From Tradewins | Ad

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Click here now!

Ahmed Hamdy Biography and Net Worth

What is Ahmed Hamdy's net worth?

How old is Ahmed Hamdy?

What is Ahmed Hamdy's salary?

How do I contact Ahmed Hamdy?

Has Ahmed Hamdy been buying or selling shares of Vincerx Pharma?

Who are Vincerx Pharma's active insiders?

Are insiders buying or selling shares of Vincerx Pharma?